All In MedTech

Device Trial Radar · NCT07856238

Long-Term Effectiveness and Safety of Sacral Neuromodulation With InterStim for Lower Urinary Tract Dysfunction

Long-Term Effectiveness and Safety of Sacral Neuromodulation With InterStim for the Management of Lower Urinary Tract Dysfunction

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

1,700

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

May 1, 2027

Study completion May 30, 2027

Sponsor

Lead sponsor
Fundación Santa Fe de BogotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medtronic
First posted
Oct 2, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This observational study will evaluate the long-term effectiveness, safety, and patient satisfaction associated with sacral neuromodulation using the InterStim™ system in adults treated for lower urinary tract dysfunction at Fundación Santa Fe de Bogotá. The study will include patients who underwent definitive InterStim implantation between January 2010 and June 2026 for conditions including overactive bladder, urgency urinary incontinence, non-obstructive acontractile detrusor, or non-obstructive urinary retention. Clinical information before implantation, details of the procedure, complications, reinterventions, device replacements, and explantations will be obtained retrospectively from medical records. Patients who can be contacted will also complete a single telephone follow-up assessment to evaluate current urinary symptoms, perceived improvement, satisfaction with treatment, catheter use, and current device status. The study aims to describe the long-term effectiveness and safety of InterStim therapy in a Colombian population, including changes in urinary incontinence, patient-reported improvement and satisfaction, complications, therapeutic failure, and device survival.

Conditions

  • Overactive Bladder (OAB)
  • Urgency Urinary Incontinence
  • Non-obstructive Urinary Retention
  • Non-obstructive Acontractile Detrusor

Interventions

  • InterStim™ Sacral Neuromodulation System II - XDevice

    Sacral neuromodulation with the InterStim™ system. Participants included in this observational study previously underwent definitive InterStim implantation as part of their clinical care. The study does not assign or administer the device as a research intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Urinary Incontinence Severity Assessed by ICIQ-UI SFTime frame: From pre-implantation to the single follow-up assessment, approximately 6 months to 17 years after implantation.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Fundación Santa Fe de Bogotá

    Bogotá, Bogota D.C., Colombia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.